Lausanne (SUI), 21 June 2016 – The FEI has announced an adverse analytical finding involving prohibited substances.

Samples taken at the 80km CEI*1 in Amman (JOR) on 21 May 2016 from the second-placed horse Obama Al Aswad (FEI ID 104DF50, ridden by Nayef Al Fayez (FEI ID 10066952), have returned positive for the banned substance Boldenone, and the controlled medications Dexamethasone, Meloxicam, Phenylbutazone and its metabolite Oxyphenbutazone.

Boldenone, an anabolic steroid, is a banned substance under the FEI’s Equine Anti-Doping and Controlled Medication Regulations (EADCMRs).

The corticosteroid Dexamethasone is used to treat inflammatory and auto-immune conditions, while the non-steroidal anti-inflammatory drugs Meloxicam, Phenylbutazone and its metabolite Oxyphenbutazone are used for pain relief.

The athlete has been provisionally suspended from the date of notification (20 June 2016). The horse has also been provisionally suspended for a two-month period.

Further details on this case can be found here.

FEI Media Contact:

Ruth Grundy
Manager Press Relations
ruth.grundy@fei.org
+41 78 750 61 45